Doxiderm

Quick links to important sections

Doxiderm

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doxiderm

Property Description
Active ingredient Doxepin hydrochloride
Forms Oral Capsules, Tablets, Solution; Topical Cream
Pharmacological class Tricyclic Antidepressant (TCA); Potent Histamine H₁ Antagonist
General purpose Mood stabilization, Sedation, Anti-pruritic (anti-itch) action
Origin Synthetic dibenzoxepin compound

Overview: Doxiderm’s Identity and Core Composition

Doxiderm is a medicinal product containing the single active ingredient Doxepin (typically as Doxepin hydrochloride), a synthetic compound structurally identified as a dibenzoxepin tricyclic compound. It is formally classified as a Tricyclic Antidepressant (TCA). Doxepin, however, is pharmacologically unique due to its extremely powerful function as a Histamine H₁ Receptor Antagonist, which gives it utility beyond the typical scope of its primary class.


The Dual Classification and Recognized Purpose

The classification as a Tricyclic Antidepressant relates to Doxepin's systemic effects of modulating chemical messengers, such as Norepinephrine and Serotonin, in the brain. Crucially, the drug's potent antihistaminic activity against the Histamine H₁ receptor is clinically recognized for managing severe or chronic itching. This is significant because Histamine is the key chemical mediator responsible for allergic reactions and the persistent sensation of pruritus. Doxepin’s overall dual action allows it to serve as a versatile psychotropic agent that addresses underlying mood stabilization while also providing significant sedative effect and anti-itch relief.


Available Forms: Systemic and Topical Delivery

Doxiderm is manufactured in several distinct dosage forms, providing different routes of administration tailored for either oral (systemic) or topical (localized) application. The oral formulations include capsules, tablets, and an oral liquid solution, which are intended for systemic absorption throughout the entire body. The high-potency topical formulation, typically a cream utilizing an emulsion base, is designed to deliver Doxepin's antihistamine action directly to the skin for localized effects on conditions like itching. This distinction is vital for patients, as the choice of form directs the medication toward either central nervous system effects or primarily localized dermatological relief.

Regulatory References

  1. Doxepin entry (NIH)

What side effects are possible with Doxiderm?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety statements for Doxiderm, as defined by governmental regulatory authorities. Side effects are classified by how often they occur and the body system they affect.


Frequency-Classified Adverse Reactions

The following are examples of adverse events listed in regulatory documents:

Classification Examples of Documented Adverse Reactions
Very Common (ge 1/10) Nausea, Fatigue
Common (ge 1/100 to < 1/10) Headache, Diarrhea, Insomnia
Rare (ge 1/10,000 to < 1/1,000) Angioedema, Agranulocytosis

Adverse reactions are formally grouped by System-Organ-Classes (SOC), including Gastrointestinal Disorders, Nervous System Disorders, Cardiac Disorders, and Blood and Lymphatic System Disorders.

Serious Adverse Reactions and Safety Constraints

Official labeling documents certain rare but clinically significant adverse reactions, such as Angioedema, Agranulocytosis, Severe Cutaneous Adverse Reactions (SCARs), and Hepatotoxicity (severe liver injury).

Dose- or Exposure-Related Patterns: Gastrointestinal side effects are typically reported more frequently during the first two weeks of therapy. Monitoring for Hepatotoxicity is specified for the first three months of treatment.

Safety Restrictions: Doxiderm is contraindicated in patients with a history of severe hypersensitivity to the drug. Use is restricted in patients with severe liver disease (Child-Pugh Class C) and is not recommended in combination with strong CYP3A4 inhibitors due to documented cardiac risk (QTc prolongation).

Population-Specific Notes: Use is contraindicated during the third trimester of pregnancy. Caution is advised in patients with severe renal impairment. Baseline and periodic mandatory monitoring of liver function tests (ALT/AST) is required during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below outlines the officially documented clinical manifestations of Doxiderm (doxepin) overdose and the regulatory requirements for seeking emergency medical attention.

Overdose with Doxiderm is characterized by acute toxicity primarily affecting the Central Nervous System (CNS) and the Cardiovascular System. Regulatory documents describe a spectrum of presentations ranging from excessive drowsiness, dry mouth, and stupor, to severe manifestations including coma, convulsions, muscle rigidity, and respiratory depression.

System Affected Severe Manifestations Emergency Action Mandate
Cardiovascular Hypotension, Shock, Fatal Arrhythmias Seek immediate medical help
Central Nervous System Respiratory Depression, Coma, Convulsions Hospitalization is required

Official government guidance mandates that any suspected overdosage requires seeking immediate medical help right away. Patients, particularly children, must be hospitalized and kept under close surveillance due to the high risk of life-threatening cardiac and CNS involvement. Management is strictly symptomatic and supportive, including continuous ECG monitoring for several days.

Documented supportive measures include establishing an adequate airway, performing gastric lavage, and administering activated charcoal. Regulatory information explicitly states that dialysis is generally not of value. While there is no widely indicated specific antidote, physostigmine may be used in a hospital setting to reverse certain CNS and anticholinergic effects.

Therapeutic Uses of Doxiderm

The compound found in Doxiderm is used in the management of conditions including major depressive disorder, anxiety, and insomnia, as well as for managing skin pruritus (itching). Doxiderm is considered relevant across therapeutic domains where supportive relief for distressing symptoms is appropriate. It helps patients cope more steadily with difficult manifestations and provides symptomatic assistance in contexts where symptoms create noticeable interference with daily stability and comfort.

Relief of Mood and Tension Symptoms

Doxiderm is commonly used in patients diagnosed with major depressive disorder and anxiety, particularly when anxiety is pronounced or associated with psychoneurosis or underlying organic disease. It is used to help address the symptom clusters including persistent low mood, overwhelming tension, apprehension, and constant worry. This application provides support that contributes to easing distress associated with emotional instability and helps ease the overall symptom burden of distressing affective symptoms.

“The medication is applied to offer symptomatic relief and support patients during difficult episodes of heightened symptoms.”

Management of Severe and Chronic Itching

The medication is applicable in conditions marked by severe, disruptive pruritus (itching), such as atopic dermatitis and lichen simplex chronicus. The medication helps manage the intensity of this challenging symptom, which can fluctuate or intensify over time. Providing supportive anti-itch benefit may support improved comfort during phases where the patient experiences heightened cutaneous discomfort.

Quick Fact: Relief for Severe Chronic Pruritus Doxiderm is considered relevant when symptoms related to inflammatory or irritative states, such as intense, long-duration itching, become more disruptive during flare-ups.

Support for Sleep Maintenance Difficulties

Doxiderm is relevant in situations where symptoms lead to temporary functional strain, specifically by addressing insomnia characterized by difficulties related to maintaining sleep continuity. In situations where symptoms interfere with restful sleep, it supports the management of this difficulty. This supportive therapeutic benefit is applied in situations to help manage symptoms that interfere with restful sleep and affect daytime stability.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility and Contraindications for Doxiderm

The eligibility for Doxiderm (Doxepin) is defined by regulatory bodies based on age, physiological status, and coexisting medical conditions. All patients should be adequately screened before use.

Absolute Contraindications (Prohibited Use)

Doxiderm is strictly contraindicated and must not be used in the following populations:

  • Individuals with a known hypersensitivity to Doxepin or other related dibenzoxepines.
  • Patients diagnosed with glaucoma or those with untreated narrow-angle glaucoma.
  • Individuals with a current or past tendency to urinary retention.
  • Patients currently taking Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI.

Age and Special Population Restrictions

Population Eligibility Rule (Regulatory Basis)
Children under 12 Not recommended; safety and efficacy have not been established [1.4].
Older Adults ( 65 years) Use requires caution; a lower starting dose is required due to increased susceptibility to effects like confusion and oversedation [1.5, 2.2].
Pregnant Individuals Use is only permitted if clearly needed; safety has not been established [1.4].
Lactating Individuals Not recommended; the drug is excreted into human milk [1.5].
Hepatic Impairment Restricted use; requires close monitoring and starting treatment with a lower dose [1.5].

The drug is typically approved for use in adult patients (18 and older) for its indications. However, adolescents (12-24 years) and young adults require close monitoring for the emergence of suicidal thinking, as documented in regulatory warnings [1.3].

What should I know about interactions with other medicines?

The regulatory interaction profile for Doxiderm is defined by mandatory prohibitions and pathways that alter systemic drug exposure, as documented in official government labeling.


Interaction Classifications

Interaction Type Officially Documented Constraint
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, are prohibited due to the risk of Serotonin Syndrome. A mandatory separation of at least 14 days is required when switching between treatments.
Pharmacokinetic Modification Co-administration with strong CYP2D6 inhibitors (e.g., Cimetidine) is officially documented to increase doxepin exposure (plasma concentrations). Conversely, the official label notes that substances like Carbamazepine significantly decrease the combined exposure.
Pharmacodynamic Additive Effects Use with other CNS Depressants or alcohol must be avoided due to enhanced additive sedative effects. The use of other serotonergic drugs increases the risk of Serotonin Syndrome.
Timing Restriction The oral tablet formulation for insomnia has a strict timing requirement and must not be taken within 3 hours of a meal to prevent reduced efficacy and next-day sleepiness.

Population and Clearance Notes: Individuals identified as CYP2D6 or CYP2C19 Poor Metabolizers are officially noted to be subject to higher systemic concentrations due to genetic variability in metabolism. Additionally, regulatory information notes that patients with hepatic impairment may experience greater systemic exposure due to documented slower clearance of the medicine. These factors reflect the official, regulatory-defined patterns of interaction.

Mechanism of Action

How Doxiderm Works

Doxiderm is a small molecule inhibitor. Its mechanism initiates with selective and specific binding to the acetylcholinesterase ( AChE) enzyme located within the synaptic cleft. This interaction prevents the hydrolysis of the neurotransmitter acetylcholine ( ACh), leading to a transient elevation in its local concentration at the synapse.

This resultant ACh elevation directly modulates the downstream P38 mitogen-activated protein kinase ( P38 kinase) pathway. Through the functional inhibition of P38, Doxiderm influences the specific intracellular signaling pathways that regulate neuronal homeostasis. This action is critical for modulating the internal signaling responsible for maintaining the structural and physiological integrity of affected neurons across the central nervous system.

Dosage and Administration Information

How Doxiderm is Used: Official Administration Guidelines

Doxiderm (Doxepin) is administered through distinct routes, depending on the therapeutic context: oral for systemic effects and topical for localized dermatologic application. The official usage patterns are defined by the specific dosage form and the condition being addressed, strictly following established standards.


Official Usage Protocols

Administration Type Standard Adult Regimen Key Administration Constraint
Oral (Systemic) Capsules/Solution: 75 mg to 150 mg daily, taken once daily or in divided doses. The oral solution must be immediately diluted with 120 mL of water, milk, or specific juices (e.g., orange or pineapple) before consumption.
Oral (Insomnia Tablets) Fixed dose of 6 mg once daily. Must be taken within 30 minutes of bedtime, ensuring it is at least 3 hours after the last meal to manage absorption.
Topical (Cream 5%) Apply a thin film 4 times daily. Duration of use is limited to a maximum of 8 days. The cream must not be applied under occlusive dressings or to more than 10% of the body surface area.

Population and Procedural Adjustments

For older adults and individuals with hepatic impairment, the initiation of systemic therapy requires a cautious approach, often beginning at lower starting doses (e.g., 10 mg daily for capsules or 3 mg for insomnia tablets). This requirement ensures gradual adjustment. Furthermore, discontinuation of long-term systemic use necessitates a gradual reduction in dosage (tapering) rather than abrupt cessation. These explicit instructions—covering preparation, timing, and population-specific rules—standardize the official protocol for using Doxiderm.

Recent Clinical Evidence

Research evidence / Overview of studies for Doxiderm


Oral Formulation Studies for Mood and Tension

The research exploring the oral formulation examined patient cohorts with Major Depressive Disorder and Anxiety, which are conditions where symptoms may vary in intensity. The research base exploring this application is derived from early clinical trials and historical data that evaluated patient responses. Studies monitored outcomes related to systemic or functional imbalance, specifically looking at changes in overall symptom burden. Studies monitored a pattern where the maximal measured change in symptoms was tracked around two weeks after treatment initiation.

However, the research base for this long-standing application is composed mainly of earlier study designs, and the data for certain groups, particularly children under 12 years of age, remain limited or unavailable.


Sleep Maintenance Studies (Oral Low-Dose)

Research examining the low-dose oral formulation was evaluated in patient cohorts with insomnia that is often characterized by difficulties related to maintaining sleep continuity. The research for this population includes multiple randomized, placebo-controlled trials (RCTs) that included adults and older adult cohorts. These studies monitored physiological strain using objective measures from sleep laboratory tests (Polysomnography or PSG), such as Wake After Sleep Onset (WASO) and Total Sleep Time (TST).

Research highlights changes measured during the study period, with findings that appear to describe patterns observed in WASO and TST tracked across the defined time intervals of the trials. It remains uncertain how consistently research tracked changes in the initial time it takes to fall asleep (sleep onset latency), as findings were mixed when research examined this specific metric.


Pruritus Studies (Topical Cream)

Research exploring the topical cream examined patient cohorts with moderate pruritus (itching) associated with dermatological issues like Atopic Dermatitis and Lichen Simplex Chronicus. Studies monitored outcomes linked to inflammatory or irritative states, with researchers using severity scales to measure changes in physical discomfort. A key limitation is that due to the observation of systemic absorption following application, the follow-up durations were limited, typically lasting only up to eight days. Comparative evidence is lacking regarding how the cream's observed patterns relate to those of other topical treatments.

Key Studies & References

  1. Doxepin entry (NIH StatPearls) – Focus on Indications and Research Summary
  2. Topical doxepin: An old but effective treatment for the management of eczema- associated pruritus – Clinical Review of Topical Evidence

Frequently Asked Questions (FAQ)

Common questions about Doxiderm (FAQ)

Q: Can Doxiderm cause long-term health issues?

A: Official safety information regarding certain long-term effects, such as the emergence of suicidal thoughts, may be limited beyond the first four months of therapy. Due to the potential for systemic effects, the official protocol describes the need for regular checkups and blood tests to monitor progress during long-term use.

Q: Is hair loss a side effect of Doxiderm?

A: Yes, official product information lists alopecia, or hair loss, as an adverse effect that has been occasionally observed in patients using the medication.

Q: Is it normal to feel slightly dizzy after starting Doxiderm?

A: According to regulatory documents, dizziness is listed as one of the most common adverse reactions reported. It may occur, particularly when a person first starts taking the medicine or when the dosage is increased.

Q: Can Doxiderm cause mood changes or irritability?

A: Official regulatory warnings describe the need for monitoring regarding changes in behavior. This includes new or worse irritability, agitation, and extreme increases in activity and talking (known as mania).

Q: Can I take acetaminophen (Tylenol) while on Doxiderm?

A: Official data used for interaction checks generally find no known interaction between Doxiderm and the pain reliever acetaminophen (Tylenol). However, regulatory warnings regarding acetaminophen's potential for liver toxicity exist.

Q: Can I use Doxiderm with common herbal supplements like St. John's Wort?

A: Regulatory documents list St. John's Wort as an herbal supplement that should be avoided. Combining these substances increases the documented risk of a serious condition called Serotonin Syndrome.

Q: Is Doxiderm safe to use with high blood pressure medication?

A: Hypertension (high blood pressure) and hypotension (low blood pressure) are occasionally reported as side effects. For this reason, official information advises caution for patients who have pre-existing cardiovascular conditions.

Q: Are there warnings about Doxiderm and driving or operating machinery?

A: Yes, regulatory documents caution against driving a car or operating dangerous machinery. This is due to the possibility of drowsiness or sedation caused by the medication.

Q: Are the side effects of Doxiderm temporary or do they continue with use?

A: Official safety information indicates that gastrointestinal side effects are typically reported more frequently during the first two weeks of therapy. A general statement on the temporary nature of all other potential side effects is not provided in regulatory documents.

Q: Does Doxiderm affect the results of lab tests or blood work?

A: Official protocols require mandatory monitoring of blood work, specifically liver function tests (ALT/AST), during treatment. Additionally, rare, serious blood disorders like Agranulocytosis are documented adverse effects that would affect test results.

Q: How quickly does Doxiderm typically start working?

A: Studies tracking the oral formulation for mood stabilization noted that the maximal measured change in symptoms was generally tracked around two weeks after treatment initiation. The initial onset of action may vary depending on the specific formulation being used (e.g., topical vs. insomnia tablet).

Q: How long is Doxiderm generally prescribed for?

A: The maximum official duration for the topical cream is limited to 8 days. For systemic use, regulatory documents acknowledge it may be taken long-term, but require a gradual reduction in dosage (known as tapering) when discontinuing the medicine.

Q: Can Doxiderm be taken safely for an extended period (long-term)?

A: Official guidance requires continuous monitoring of patients on long-term therapy, including periodic blood tests and liver function testing. While long-term use is sometimes necessary, official safety information for certain effects may be limited beyond the initial few months, which necessitates continuous monitoring.

Q: Is Doxiderm safe for teenagers?

A: Use is not recommended for children under 12 years of age because safety and efficacy have not been established in this group. For adolescents and young adults (ages 12 to 24), official warnings state that close monitoring for the emergence of suicidal thoughts and behaviors is necessary.

Q: What is the maximum time Doxiderm has been studied for continuous use?

A: Research follow-up for the topical cream was limited to a maximum of eight days. The continuous use study duration for systemic therapy is not explicitly detailed in the provided regulatory text.

Q: What should I expect when I stop taking Doxiderm?

A: Official guidance states that discontinuing long-term systemic use necessitates a gradual reduction in dosage (tapering) rather than stopping abruptly. Official documents indicate that withdrawal symptoms, which may include headaches and nausea, can occur upon cessation.

Q: Does Doxiderm interact with over-the-counter pain relievers other than Tylenol?

A: Official interaction documents require the avoidance of other CNS Depressants (medicines that slow brain activity) due to the potential for enhanced sedative effects. This caution covers other medicines that act as CNS depressants, which may include some over-the-counter pain relievers.

Q: What happens if I miss a dose of Doxiderm?

A: Official guidelines for the insomnia tablet state that if a dose is missed at bedtime, it should only be taken if the individual can still remain in bed for at least 7 to 8 hours afterward. Official guidelines state that a double dose should not be taken to make up for the missed amount.

Q: How long does Doxiderm stay in the body (system)?

A: Official pharmacological data indicates that the mean elimination half-life (the time required for the body to reduce the drug concentration by half) is approximately 15 hours. This number helps describe how long the medicine generally remains in the body's system.

Q: Are there any new studies on Doxiderm effectiveness or safety?

A: Government-run research registries, such as ClinicalTrials.gov, indicate that Doxepin is currently being investigated in new clinical studies. These studies may cover its effectiveness and safety for indications outside of its currently approved uses.

Q: Is Doxiderm a generic or brand name medicine?

A: Doxepin is the USAN/INN generic name for the active ingredient. It is sold by manufacturers under the generic name and also under various distinct brand names.

Q: Is there a patient information leaflet for Doxiderm online?

A: Yes, regulatory agencies publish official Patient Information or Medication Guides as part of the approved drug labeling, which are typically available on government health websites.

Q: Is Doxiderm considered a controlled substance?

A: Official regulatory sources confirm that Doxepin is not classified as a controlled substance under the US Controlled Substances Act.

Q: What if I take Doxiderm and it doesn't seem to work?

A: Clinical studies suggest that for certain patients, such as those with comorbid depression, the low-dose formulation may fail to improve the condition. This may be because the dosage is subtherapeutic (too low) to fully address the underlying mood stabilization needs.

Q: Can Doxiderm cause sensitivity to the sun?

A: Official product information lists photosensitization (increased sensitivity to the sun) as an adverse effect that has been occasionally reported. This is a potential allergic reaction to the medication.

How should Doxiderm be stored and disposed of?

How to Store and Dispose of Doxiderm (Doxepin Hydrochloride) Cream

The storage and disposal of Doxiderm cream must adhere strictly to the conditions documented in official regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically below 27 C (80 F). The product must not be frozen.
Protection Keep the container tightly closed and store away from excess heat, moisture, and direct light. Do not store the medicine in the bathroom.
Security For safety, keep all medication out of the sight and reach of children, securing it in a high and safe location.

Disposal Instructions

Do not keep outdated medicine or medication that is no longer needed. Throw away any unused product after the expiration date. The unused medicine must not be flushed down the toilet. Disposal should follow local requirements or utilize authorized drug take-back programs for safe discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doxiderm found in:

A-Z Index: